Friday, 16 October 2026European Markets

PROXIMUS And DEKUPLE Have A High Dividend Yield And Return On Equity In The Communication Services Sector.

Loading stream...

(vianews) - proximus (prox.br) is among this list of stock assets with the highest dividend rate and return on equity on the communication services sector.

financial asset price forward dividend yield return on equity
proximus (prox.br) €7.50 19.12% 13.04%
dekuple (dkupl.pa) €28.40 3.32% 33.47%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. proximus (prox.br)

19.12% forward dividend yield and 13.04% return on equity

proximus plc provides digital services and communication solutions in belgium and internationally. it operates through domestic, international carrier services, and telesign segments. the company offers fixed and mobile telephony, internet, and television services to residential customers and small businesses, and ict services to residential, business, and telecom wholesale markets. it also provides managed and platform, integrating networking, cloud, cybersecurity, business application, and data and artificial intelligence services. in addition, the company offers international delivery authentication and digital identity services to internet brands, digital champions, and cloud native businesses. it offers its products and services under proximus, scarlet, mobile vikings, tango, telindus, and telindus netherlands brands. the company was formerly known as belgacom sa and changed its name to proximus plc in june 2015. proximus plc was founded in 1930 and is headquartered in brussels, belgium.

earnings per share

as for profitability, proximus has a trailing twelve months eps of €1.33.

pe ratio

proximus has a trailing twelve months price to earnings ratio of 5.64. meaning, the purchaser of the share is investing €5.64 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.04%.

earnings before interest, taxes, depreciation, and amortization

proximus's ebitda is 0.97.

volatility

proximus's last week, last month's, and last quarter's current intraday variation average was a negative 0.69%, a negative 0.79%, and a positive 1.74%.

proximus's highest amplitude of average volatility was 1.10% (last week), 1.83% (last month), and 1.74% (last quarter).

more news about proximus.

2. dekuple (dkupl.pa)

3.32% forward dividend yield and 33.47% return on equity

adlpartner sa provides marketing solutions in france and internationally. the company markets and sells press subscriptions; and offers cross-channel marketing solutions and insurance brokerage services. it also provides consulting and technology, marketing engineering, and creator of customer relation services. the company was founded in 1972 and is based in montreuil, france. adlpartner sa is a subsidiary of sogespa sas.

earnings per share

as for profitability, dekuple has a trailing twelve months eps of €2.55.

pe ratio

dekuple has a trailing twelve months price to earnings ratio of 11.14. meaning, the purchaser of the share is investing €11.14 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 33.47%.

moving average

dekuple's value is above its 50-day moving average of €26.60 and under its 200-day moving average of €29.25.

dividend yield

as maintained by morningstar, inc., the next dividend payment is on jun 21, 2023, the estimated forward annual dividend rate is 0.88 and the estimated forward annual dividend yield is 3.32%.

more news about dekuple.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com